The purpose of this policy is to define the prior authorization process for Botox® (onabotulinumtoxinA), Dysport® (abobotulinumtoxinA), Mybloc® (rimabotulinumtoxinB), and Xeomin® (incobotulinumtoxinA).

Botox® (onabotulinumtoxinA) is indicated for:
- Treatment of strabismus in patients ≥12 years of age
- Treatment of blepharospasm associated with dystonia, including benign essential blepharospasm or VII nerve disorders in patients ≥12 years of age
- Treatment of cervical dystonia, spasticity in the flexor muscles of the elbow, wrist, and fingers in adult patients, to reduce the severity of abnormal head position and neck pain
- Treatment of severe, primary axillary hyperhidrosis that is inadequately managed by topical agents in adult patients
- Prophylaxis of headaches in adult patients with chronic migraine (>15 days per month with headache lasting 4 hours a day or longer)
- Treatment of urinary incontinence due to detrusor overactivity associated with a neurologic condition [e.g., spinal cord injury (SCI), multiple sclerosis (MS)] in adults who have an inadequate response to or are intolerant of an anticholinergic medication
- Treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency, in adults who have an inadequate response to or are intolerant of an anticholinergic medication
- Treatment of upper and lower limb spasticity in adult patients
- Treatment of upper limb spasticity in pediatric patients 2 to 17 years of age
- Treatment of lower limb spasticity in pediatric patients 2 to 17 years of age

Dysport® (abobotulinumtoxinA), is indicated for:
- The treatment of adults with cervical dystonia to reduce the severity of abnormal head position and neck pain in both toxin-naïve and previously treated patients
- Spasticity in adults
- Treatment of lower limb spasticity in pediatric patients 2 years of age and older
- The treatment of upper limb spasticity in pediatric patients 2 years of age and older

Mybloc® (rimabotulinumtoxinB) is indicated for the treatment of adults with:
- Cervical dystonia, to reduce the severity of abnormal head position and neck pain associated with cervical dystonia
- Chronic sialorrhea
Xeomin® (incobotulinumtoxinA) is indicated for the treatment of:

- Cervical dystonia in adults
- Chronic sialorhrea in adults
- Upper limb spasticity in patients age 2 years and older, excluding spasticity caused by cerebral palsy
- Blepharospasm in adults previously treated with Botox® (onabotulinumtoxinA)

Although similar in certain aspects, it is important to understand that Botox®, Dysport®, Mybloc®, and Xeomin® are unique products that are not interchangeable. The units of biological activity of one botulinum toxin product cannot be compared to or converted into units of any other botulinum toxin product.

FDA has determined that post-marketing safety data from approved botulinum toxins suggest that botulinum toxin effects may, in some cases, be observed beyond the site of local injection. Based upon this new safety information, FDA has required that the manufacturers of botulinum toxin products add a boxed warning regarding the distant spread of toxin effect to the package insert and implement a Risk Evaluation and Mitigation Strategy (REMs), including the requirement for the distribution of a Medication Guide each time a patient is injected with a botulinum toxin product.

**PROCEDURE**

**Initial Authorization Criteria:**

*Must meet all of the criteria listed under the respective diagnosis:*

1. **Botox® (onabotulinumtoxinA):**
   - Must have a diagnosis of:
     - Strabismus
     - Blepharospasm associated with dystonia including benign essential blepharospasm or VII nerve disorders in patients greater than 12 years old
     - Cervical dystonia (spasmodic torticollis)
     - Spasticity in the flexor muscles of the elbow, wrist or fingers in adults
     - Spasticity in the upper limb(s) in patients 2 years of age and older
     - Spasticity in the lower limb in:
       - Adults
       - Pediatric patients 2 to 17 years of age
     - Severe primary axillary hyperhidrosis that is inadequately managed by topical agents
       - Must be prescribed by a dermatologist
       - Must have tried 10-20% topical aluminum chloride with an inadequate response or adverse effect of a severe rash
     - Chronic migraine (to be used for prophylaxis of headaches in adult patients)
       - Must be prescribed by a neurologist
- Must be 18 years of age or older
- Must have all of the following:
  - Headache occurring on 15 or more days per month for at least 3 consecutive months
  - 8 or more of the total headache days each month being migraine or probable migraine days
  - Having >4 distinct headache episodes each lasting >4 hours a day or longer
- Must not be using opioids >10 days per month
- Must have an adequate trial (of at least 2 months each) of 3 prophylactic therapy classes to include beta-blockers, anticonvulsants, and tricyclic antidepressants (TCAs) with an inadequate response
  - For members in whom one of these therapy classes is not clinically appropriate and/or members with significant side effects/intolerance to one of these therapy classes, additional prophylactic therapy classes may be considered. Additional prophylactic therapy classes to consider are calcium channel blockers, selective serotonin reuptake inhibitors (SSRIs), selective norepinephrine reuptake inhibitors (SNRIs), or angiotensin converting enzyme inhibitors (ACEIs).
- Urinary incontinence due to detrusor overactivity associated with a neurologic condition in adults who meet the following criteria:
  - Must have a previous trial and failure of an anticholinergic medication
- Overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency, in adults who meet the following criteria:
  - Must be prescribed by a urologist or a fellowship-trained urogynecologist
  - Must have > 3 urinary urgency incontinence episodes in a 3-day period
  - Must have > 8 micturitions per day
  - Must provide chart documentation showing specific examples of how quality of life is impacted by disease (e.g. sleep disturbances, work disruption, decrease in social interactions, etc.)
  - Must have a trial and failure of behavioral therapy (includes but not limited to weight loss, dietary changes, exercise, etc.)
  - Must have an adequate trial (of at least 4 weeks) at the recommended dose of 2 anticholinergic medications with an inadequate response or intolerance

2. **Dysport® (abobotulinumtoxinA):**
   - Must have a diagnosis of:
     - Cervical dystonia (spasmodic torticollis) in adults
     - Spasticity in adults
     - Spasticity in the lower limb(s) in children 2 years of age and older
     - Spasticity in the upper limb(s) in children 2 years of age and older
3. Mybloc® (rimabotulinumtoxinB):
   - Must have a diagnosis of:
     o Cervical dystonia (spasmodic torticollis)
     o Chronic sialorrhea

4. Xeomin® (incobotulinumtoxinA):
   - Must have a diagnosis of one of the following:
     o Cervical dystonia (spasmodic torticollis) in adults
     o Blepharospasm in adults
       o Must have previously been treated with Botox
     o Spasticity in the upper limb(s) in patients age 2 years and older, excluding spasticity caused by cerebral palsy
     o Chronic sialorrhea in adults

Maryland Physicians Care also acknowledges the following diagnoses for consideration of coverage per the American Academy of Neurology Therapeutics and Technology Assessment Subcommittee evidence based review, category Level A (established as effective for the given condition in the specified population in at least two consistent class I studies) or Level B (probably effective for the given condition in the specified population in at least one class I study or at least two class II studies) evidence showing efficacy:

1. Autonomic Disorders
   - Axillary hyperhidrosis subject to previously noted criteria
   - Neurogenic detrusor overactivity in adults after trial and failure of at least one previous agent
   - Detrusor sphincter dyssynergia after spinal cord injury
   - Drooling in Parkinson’s Disease

2. Spasticity
   - Spasticity in adults due to stroke, trauma, multiple sclerosis, and neoplasm involving the CNS.
   - Spasticity due to cerebral palsy, brain injury, spinal cord injury, stroke, multiple sclerosis, or encephalopathy in children.

3. Movement Disorders
   - Blepharospasm
   - Cervical dystonia
   - Focal upper extremity dystonia
• Adductor laryngeal dystonia
• Essential hand tremor in patients after trial and failure of at least one previous agent

**Reauthorization Criteria:**
All prior authorization renewals are reviewed on an annual basis to determine the Medical Necessity for continuation of therapy. Authorization may be extended at one-year intervals based upon chart documentation from the prescriber that the member’s condition has improved based upon the prescriber’s assessment while on therapy. Additionally, the following criteria must be met for the conditions listed below:

- Chronic migraine:
  - Chart documentation from the prescriber indicating that the member’s chronic migraines have been reduced in frequency and/or severity as a result of therapy as per patient headache journal.

- Overactive bladder:
  - Chart documentation from the prescriber indicating that the member has at least 2 urinary incontinence episodes in a 3-day period.

**Limitations:**

<table>
<thead>
<tr>
<th>Length of Authorization (if above criteria met)</th>
</tr>
</thead>
</table>
| Initial Authorization | 1 course of treatment (3 months)  
| Reauthorization | OAB: 6 months  
| | All other conditions: 1 year  
| **Quantity Limits** |  
| **Botox®** |  
| | 100 U vial: 4 vials per 84 days  
| | 200 U vial: 2 vials per 84 days  
| **Dysport®** |  
| | 2 vials per 84 days  
| **Myobloc®** |  
| | 2,500 U vial: 4 vials per 84 days  
| | 5,000 U vial: 2 vials per 84 days  
| | 10,000 U vial: 1 vial per 84 days  
| **Xeomin®** |  
| | 50 U vial: 8 vials per 84 days  
| | 100 U vial: 4 vials per 84 days  
| | 200 U vial: 2 vials per 84 days  

If the established criteria are not met, the request is referred to a Medical Director for review, if required for the plan and level of request.

**Codes: J Code(s)**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>J0585</td>
<td>Injection, onabotulinumtoxina, 1 unit</td>
</tr>
</tbody>
</table>
REFERENCES


